summari report sale
compar ex-fx came
ahead consensu estim
respect non-gaap ep in-lin
estim consensu in-lin ep somewhat
disappoint view given robust top-lin growth
notabl pipelin updat today call delay
mdt surgic robot due issu final softwar hardwar
end fy initi commerci launch ou fy
intend provid updat timelin investor
day june regard guidanc reiter fy sale
guidanc compar ex-fx growth includ
compar ex-fx growth bottom-lin
manag re-affirmed fy non-gaap ep growth outlook
ex-fx adjust pmr patient monitor
recoveri divestitur plan provid formal fy
guidanc call manag gave
increment earli color next fiscal year mdt preliminari fy
growth consist long-rang plan high-single-digit
non-gaap ep growth compar ex-fx base mdt
preliminari commentari analysi believ math
impli report fy ep rang see figur
chang model rais fy sale estim
compar ex-fx basi
decreas fy non-gaap ep estim
report increas fy sale estim
compar ex-fx basi
non-gaap ep estim report
maintain price target base cy
ep estim
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort reflect combin follow
acquisit cov
compani prioriti stock list
compani data secur llc estim reuter
 recap report sale compar ex-fx came
ahead consensu estim respect
contribut growth quarter make top-lin result even
impress view non-gaap ep compar ex-fx in-lin
estim consensu in-lin ep rel model reflect higher revenu off-set
lower gross margin vs estim higher opex vs
estim wed note gross margin declin y/i compar ex-fx basi oper
margin improv prior year period driven primarili reduct
sg spend somewhat off-set neg impact fx top-lin growth
encourag view in-lin ep somewhat disappoint
larg cap med-tech organ growth appear highest last year
report tuesday morn aggreg growth rate larg
cap med-tech name see figur analysi indic world-wide organ ex-fx growth
acceler sequenti nearli fastest quarterli growth rate last three
year start analysi annual basi cy growth declin roughli bp
stack two-year basi organ growth acceler
growth highest level seen past two year see figur
strong acceler appear driven enhanc season high
deduct healthcar plan potenti catch-up hurrican improv
af lvad lead crhf growth mdt crhf cardiac rhythm heart failur busi grew
ex-fx compar ex-fx high power icd implant
cardiovert defibril crt-d cardiac resynchron therapi defibril declin high-
singl digit competitor receiv mri label respect high-voltag devic
recent month low power pacemak grew low-singl digit world-wide basi crt-p
cardiac resynchron therapi pacemak grew excess behind recent launch quad
portfolio base competitor result estim world-wide ww market
declin ex-fx mdt af atrial fibril solut grew high-teen
essenti line last quarter high-teen growth diagnost reveal linq grew mid-singl
digit low-doubl digit growth regard htwr estim lvad left ventricular
assist devic contribut roughli cvg sale wed note lvad busi
benefit level defer sale quarter
evolut continu drive strong tavr growth csh coronari structur heart revenu grew
ex-fx behind low growth ex-fx transcathet aortic valv replac tavr
compar high growth mdt us tavr busi grew mid driven
continu uptak mdt evolut devic expans us intermedi risk popul
estim global tavr market grew ex-fx slight acceler compar growth
estim us market grew compar wed note
tavr model includ pulmon sale declin due share loss ew growth rate
model modestli lower report
de growth see step behind resolut onyx said ww de drug-elut stent
grew mid-teen compar low-singl digit growth de result
includ mid growth us meaning better mid-singl digit growth previou
quarter de growth mid-single-digit ou roughli flat prior quarter
result reflect continu launch resolut onyx us japan estim
share us ww de market
dcb growth lead apv busi aortic peripher vascular apv sale grew ex-
fx modest acceler growth ex-fx within apv aortic grew low-single-
digit peripheral/endoven grew mid-singl digit peripher growth led mdt
inpact admir dcb drug coat balloon grew low-teen deceler vs growth
high-teen estim roughli share us dcb market vs bcr
philip
global spine flat y/i ex-fx strength bmp off-set weak global spine
sale flat y/i ex-fx in-lin global spine market strength bmp bone
morphogenet protein off-set weak core spine result driven intern sale
off-set y/i declin unit state manag note spine revenu would y/i
coupl enabl technolog imag navig power system nerv monitor
robot report compani neurosurgeri segment believ
relev comparison versu peer indic overal growth spine procedur
segment mdt global core spine sale declin low-singl digit similar declin unit
state flat y/i growth ou bright spot core spine quarter acceler greater
china latin america continu account penetr o-arm implant pull strong growth
cervic arthroplasti led prestig lp mdt global infus sale mid-singl digit
driven low growth intern market mid-singl digit growth global infus
growth repres acceler y/i post final intervent spine sale
high-singl digit global driven new product launch osteocool
strength all-bon indic strong balloon kyphoplasti perform asia
global spine market growth deceler global spine market growth ex-
infus y/i repres deceler y/i post
global growth driven intern market y/i off-set weak unit
sate spine market ex-infus declin y/i repres
deceler throughout year ou spine
market growth ex-infus y/i compar growth
spine market could improv note spine market experienc procedur volum
growth versu off-set reduct price similar net flat market
growth manag believ market could flat next coupl quarter
also note new insight term driver growth price pressur
remain key neg factor hospit vendor consolid greater sophist
hospit buy pattern well tender process expect net share taker driven
implant pull enabl technolog off-set price pressur led vendor consolid
spinal robot aid overal spine growth posit see increment implant pull
drive share gain given relationship mzor first compani begun place
mazorx account gener up-front system revenu second compani expect see
implant pull system typic six month lag contract take effect
meaning revenu book third compani mzor integr broader spine
enabl technolog navig imag decemb time-frame advanc
featur work implant technolog tie platform drive further-pul
revenu growth
pain therapi rebound pain therapi sale grew ex-fx reflect
high-single-digit increas spinal cord stimul pain pump high-single-digit growth
intervent spine estim ww sale equat y/i growth
ex-fx estim us sale includ mdt result
market model estim broader ww market grew ex-fx
meaning sequenti acceler vs estim us market grew
accord model first time sinc
post posit us growth attribut improv launch intelli
implant puls gener evolv workflow
neurovascular growth remain robust mdt neurovascular revenu grew high-teen
somewhat growth rang consist growth compani
attribut strong perform double-digit growth nearli region global
momentum stroke portfolio includ growth solitair stent retriev similar
sens recent posit stroke data defus isc intern stroke
confer januari help maintain growth momentum follow dawn data
present may dawn defus show endovascular treatment stroke
benefit patient beyond initi window onset potenti extend treatment window
hour note syk neurotech sale grew us driven stroke
coil product grew mid- high-teen ou
mitg growth acceler busi region face tougher comp
mitg sale total compar ex-fx growth recal mitg compris
surgic innov si respiratori gi renal sold patient deep vein
thrombosi nutrit insuffici busi juli si sale grew compar ex-
fx vs sale grew compar ex-fx vs region
growth led emerg market compar ex-fx us sale improv
vs guid mitg compar ex-fx growth step
due part time rampant flu season benefit tough
prior year comp beyond expect mitg maintain mid-singl digit growth
beyond despit delay surgic robot platform
overal growth momentum improv surgic innov si within si advanc surgic
maintain growth high-single-digit growth gener surgic bounc back low-
single-digit declin mid-single-digit growth point stabil procedur
volum key driver advanc surgic growth quarter product compani
highlight strength advanc stapl reflect continu momentum signia power stapler
tri-stapl specialti reload advanc energi driven valleylab energi platform
ligasur portfolio comparison organ growth jnj advanc surgeri improv
busi boost gain follow mdt suppli challeng
hurrican maria improv mdt gener surgic growth reflect strong world-wide
perform electrosurgeri improv wound closur servic manufactur capac
continu increas comparison jnj gener surgeri sale growth improv
jnj perform help suppli issu
strong sutur perform
growth acceler driven respiratori gi sale rose ex-fx
improv ex-hurrican maria growth acceler quarter
driven low-singl digit growth respiratori gi reflect strong adopt microstream
monitor product higher nellcor puls oximetri sale relat strong flu season howev
sale renal solut fell low-singl digit vs low- mid-singl digit growth
bellcor sale temporarili affect time distributor contract delay
commerci integr certain market howev renal access growth remain strong emerg
surgic robot delay updat june call compani push back
timelin surgic robot launch due issu final softwar hardwar integr
previous target first-in-man sometim next coupl month end fy
recal last investor day compani highlight robot program could contribut
growth mitg minim invas therapi group busi roughli
million revenu updat timelin provid call said remain confid
technolog aim provid updat upcom investor day june
diabet return double-digit growth global diabet sale y/i ex-fx
repres turnaround declin post fq turnaround
driven versu non-develop growth acceler
versu diabet busi experienc sensor suppli issu recent
quarter result stronger-than-expect demand pump us pump
europ compani improv abil meet patient demand behind increas sensor capac
expans remain on-track meet predict sensor demand exist new user
end expect double-digit growth segment continu expect
double-digit growth aid increas sensor suppli strong demand pump
look diabet sub-seg intens insulin manag iim busi post growth
high-teen revers versu declin low-singl digit post non-intens diabet
therapi ndt revenu declin mid-singl digit versu declin post
diabet servic solut dss revenu mid-singl digit versu flat y/i
em growth remain solid emerg market em revenu grew y/i ex-fx last
quarter accord manag em growth balanc across geographi china
europ latin america middl east africa southeast asia grew double-digit
em sale quarter account revenu last quarter nearli in-lin
estim large-cap med-tech median current estim median em growth
rate large-cap med-tech compani ex-bcr around ex-fx
fy outlook reiter guidanc introduc earlier tuesday re-affirmed
fy sale guidanc compar ex-fx basi bottom-lin reiter
outlook fy non-gaap ep growth ex-fx adjust divestitur regard
manag guid top-lin growth compar ex-fx non-gaap ep growth
compar ex-fx mdt sale growth outlook busi follow ex-
fx cvg ex-fx mitg ex-fx rtg double-digit growth diabet
manag expect fx approxim tailwind sale current rate
anticip fx impact non-gaap ep
addit fy commentari provid expect formal give fy guidanc
call manag provid addit preliminari thought expect next
fiscal year expect drive mid-single-digit compar ex-fx top-lin growth consist
long-rang plan fy non-gaap ep growth high-single-digit compar ex-fx mdt
preliminari outlook ep reflect lower expect interest incom anniversari full-
year benefit stock base compens account chang begin
transit servic agreement relat divestitur mdt fy preliminari sale outlook
busi remain unchang updat call expect mid-single-digit growth
cvg mitg rtg diabet expect grow double-digit regard fx compani
expect roughli tailwind sale posit impact non-gaap ep addit
expect dilut associ pmr patient monitor recoveri divestitur
fy base mdt preliminari commentari analysi believ math impli report
fy ep rang see figur
note organ growth adjust fx acquisitions/divestitur sell day weather meaning
note organ growth adjust fx acquisitions/divestitur sell day weather meaning
organ med-tech pf average excl growth year stack med-tech pf average excl medtron plc
price target nc
price target assum cy cash ep estim risk includ
weak key end market greater share loss model delay product launch
believ deliv averag organ growth due lull major new product launch
combin competitor headwind
found minneapolis-bas lead global medic technolog compani
focus provid therapi chronic diseas compani four primari busi cardiac
medtron plc pro-forma quarterli statementsin million except per share datafisc year end etot net currenc y-i excl pmr expensesresearch oper incomenet interest expens amort incom tax incom adj continu year-to-year incom year-to-year incom dilut share year-to-year adjust pmr divestitur not-adjustedsourc compani report secur llc estim medic technolog
vascular restor therapi minim invas therapi diabet revenu
